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Uncertainty has recently been expressed as to the role of
SFA for the development of atherosclerosis and CHD(1). This
confusion, created primarily by interpretation of results
from prospective cohort studies(2), was recently thoroughly
discussed with strong emphasis on the shortcomings of such
studies(3). The seriousness of the problem makes it desirable
to broaden the scope of this discussion with a main focus
on the public health implications.
Confusion in the scientific literature on these issues may
easily be misused by the food industry to promote their
interests. More serious, however, is the potential damage this
uncertainty may cause to public health strategies and the
priority given to saturated fat and serum LDL-cholesterol
reduction in the prevention of CHD. Thus, an important
report on non-communicable diseases (NCD) recently pub-
lished as an input to the forthcoming UN High-Level Meeting
(UN HLM) in September 2011 listed tobacco control and salt
reduction as its top priorities among the well-known risk
factors for NCD(4). Furthermore, at the recent conference of
Global Health Ministers in Moscow, the WHO listed smoking
cessation, alcohol controls and dietary salt reduction as
particularly cost-effective interventions to reduce the risk
of NCD while also giving special attention to the promotion
of healthy diets (low in SFA, trans-fatty acids (TFA), salt
and sugar, and high in fruit and vegetables)(5). In the draft out-
come document of the HLM on the prevention and control of
NCD, cost-effective measures to reduce risk factors mentioned
are: tobacco and alcohol control; reducing salt and sugar
intake; replacing trans-fats in foods with polyunsaturated
fats; promoting public awareness about diet; and physical
activity(6). Thus, among risk factors, the role of SFA reduction
and serum LDL-cholesterol reduction are listed but not speci-
fically mentioned as priority tasks.
We agree with these reports in their emphasis on the
multiple risk factors and urgency for action. Our main con-
cern, however, is to emphasise the importance of lowering
SFA intakes to reduce blood LDL-cholesterol levels at a time
when there are tendencies to downplay the importance of
SFA(1,7,8). There have been substantial reductions in mortality
from CVD in North America, Western Europe and Australasia
over the last 30 years that reflect successful national public
health policies to reduce the intakes of SFA, in addition to
promoting smoking cessation and controlling blood pressure.
Nevertheless, excessive intakes of SFA remain a major public
health problem not only in affluent countries but are also
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now a major and increasing problem in low- and middle-
income countries where 80 % of cardiovascular deaths occur.
Recent critics of the role of SFA have questioned the rigour
of the early dietary trials of CVD prevention and questioned
current public health policy on limiting the intake of SFA(8);
they suggest that more attention should be paid to increased
intake of PUFA(9). The trials demonstrate unequivocally that
replacing SFA, largely from dairy and meat fats (but in the
Leren trial also with some TFA), by PUFA reduces serum
cholesterol levels and CHD risk(9). That replacement of SFA
by a variety of carbohydrate-containing foods also reduces
CHD risk may be inferred from ecological studies, e.g. in
Finland. CHD was also almost non-existent in rural China
when mean cholesterol levels were approximately 3·5 mmol/l
(1350 mg/l), with total fat intakes only about 15 % of energy
and extremely low intakes of SFA(10,11). These observations,
replicated in many other countries, should not be ignored
even if meta-analyses of prospective cohort studies suggest
no independent associations of SFA intake with CHD risk(2).
The null results of the latter studies(2) probably reflect
measurement error, residual confounding, over-adjustment
by covariates on the causal pathway and large variations in
plasma cholesterol compared to variations in intake of dietary
fat(3,12–15). The role of SFA risks may also be overlooked,
given the strong emphasis on TFA(16) and the incorrect pro-
position that the CHD epidemic in affluent societies has
been primarily linked to a high consumption of TFA(17).
Atherosclerosis is the pathological basis of CHD and other
CVD. Extensive research over the last century has established
that atherosclerosis is a complex process in which disturbed
lipoprotein metabolism plays a critical role. Elevated levels
of apo B containing cholesterol-rich lipoprotein particles
drive the development of atherosclerosis in humans and in
experimental animals, even in the absence of other known
risk factors(18). Accumulation of these LDL particles in the
intima and binding of apo B to the extracellular proteoglycans
appear to be the initial step in atherosclerosis(19) with further
triggering of inflammatory reactions(20). The amount and
type of dietary fat to a large extent determines the number
of circulating LDL particles and blood levels of total choles-
terol. Moreover, SFA with 12–16 carbon atoms are the most
potent LDL- or total-cholesterol-raising fatty acids(21).
Recently, several studies have quantified the proportion of
the decline in CHD mortality that is explained by changes in
risk factors and treatment. Ford & Capewell estimated that
almost half to three-quarters of the lower CHD mortality in
the USA may be explained by risk factor reduction, with the
remainder being attributed to more effective treatment for dys-
lipidaemia and hypertension(22). Further studies in European
populations also suggest that reduction in CVD risk factors is
more important than improvements in treatment. The relative
importance of the different risk factors in different populations
will of course depend on the magnitude of change. In the USA,
24 % of the decline in CHD mortality has been ascribed to a
reduction in total cholesterol(22). However, in the Nordic
countries where national preventive programmes have been
conducted since the early 1960s, dietary changes with a
reduction in population mean total cholesterol explain a far
greater proportion of the decline in CHD mortality.
Finland has experienced an over-80 % fall in CHD mortality
due to a large extent to the reduction in total cholesterol(23);
lower blood pressure and less smoking in men amplify this
cholesterol-lowering benefit(23,24). In Finland, a reduced SFA
intake was the main reason for the fall in blood cholesterol
caused by a massive decline in dairy fat consumption(25).
The intake of TFA from partially hydrogenated oils has
always been low in Finland; so its removal cannot explain
either the reduction in blood cholesterol or the impressive
fall in CHD mortality(25). By contrast, in Norway, the consump-
tion of TFA was high and its removal may explain part of the
decline in national cholesterol levels. However, the major part
of the reduction was explained by reduced SFA intake(26).
Similar analyses have recently been reported for Iceland
where lowering of cholesterol accounted for 32 % of the
CHD mortality reduction(27). In all these Nordic populations,
a modest initial increase in PUFA intake (which has,
however, been stable for the last 25 years at 5–6 % of
energy) may have contributed to the early but not the later
fall in blood cholesterol.
These examples illustrate the substantial benefits of reduc-
ing intake of SFA. While we would strongly endorse the
high priority given to smoking and salt reduction made else-
where(4), we would consider the evidence for a reduction
in intake of SFA by reducing intake of animal- and high-SFA-
containing vegetable fat sources to be even stronger than
when this policy was introduced by the WHO in the early
1980s. It should therefore also be included in the highest
priority category. We approve of the relatively simple and
cost-effective measures for the food industry, highlighted by
the reports proposing removing salt and most TFA from the
food supply. However, TFA removal must not sidetrack us
from the very substantial quantitative importance of reducing
SFA from the food supply.
SFA reduction has proven exceptionally cost-effective; so
governments should not be distracted by industrial pressure
or problematic new analyses of prospective studies to
change dietary policies which in affluent societies have been
remarkably successful in limiting CVD before the role of
TFA became clear. The WHO should continue to support the
member states based on its earlier successful policy about
saturated fats in order to combat the burden of CVD now
arising in poorer countries as saturated fat intakes escalate.
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